Document is current
Any future updates will be listed below
-
Authors
Basnyat, Pabitra
Järvenpää, Soila
Raitanen, Jani
Pesu, Marko
Lehtimäki, Kai
Peltola, Jukka
- License Information
-
More Information
Article History
Received: 3 February 2021
Accepted: 17 June 2021
First Online: 2 July 2021
Competing interests
: J. P. has participated in clinical trials for Eisai, UCB, and Bial; received research grants from Eisai, Medtronic, UCB, and LivaNova; received speaker honoraria from LivaNova, Eisai, Medtronic, Orion Pharma, and UCB; received support for travel to congresses from LivaNova, Eisai, Medtronic, and UCB; and participated in advisory boards for LivaNova, Eisai, Medtronic, UCB, and Pfizer. K. L. has received consultation fees and speaker honoraria from Medtronic and Abbott (formerly St. Jude Medical). S. J. has received study grants from the Finnish Epilepsy Research Foundation, Maire Taponen Foundation, Finnish Medical Foundation and Instrumentarium Science Foundation. P. B., J. R. and M. P. report no disclosures.
